The major U.S. equities indexes were mixed at midday Thursday, with the Dow Jones Industrial Average down close to 400 points ...

If approved, the pill is expected to be far easier to administer than current injectables — and far easier to manufacture.

UnitedHealth plunged 22% and kept the blue-chip Dow in negative territory after the insurer lowered its annual profit ...

Pharmaceutical companies—including Eli Lilly and Novo Nordisk, which currently dominate the obesity market—have been testing ...

Eli Lilly said its new weight-loss pill had cleared a late-stage clinical trial, a promising sign as the company continues to ...

Eli Lilly is getting closer to bringing a weight loss pill to market, but CEO David Ricks notes certain factors need to be considered to prevent prices from ballooning.

Eli Lilly is getting closer to bringing a weight loss pill to market, but CEO David Ricks notes certain factors need to be considered to prevent prices from ballooning. The Trump administration ...

Lilly said its investigational once-daily pill achieved positive topline results in a late-stage study evaluating the safety and efficacy of orforglipron compared with a placebo in adults with type 2 ...

The UnitedHealth slide weighed heavily on the Dow, which fell 527 points, or 1.3%.

In this article, we are going to take a look at where Eli Lilly and Company (NYSE ... according to S&P Dow Jones Indices. Dividend stocks have been performing well this year, even as broader ...

U.S. stocks saw mixed movements as UnitedHealth plunged 22% after a weak earnings report, dragging the Dow down 527 points.

BENGALURU: Wall Street stocks ended mixed on Thursday, lifted by Eli Lilly and Apple ... declined 0.13% to 16,286.45 points, while the Dow Jones Industrial Average declined 1.33% to 39,142. ...